Syndax Pharmaceuticals IncSNDX

Syndax Pharmaceuticals Inc (SNDX) is having a rough go of it, with operating losses of $34.2 million in the latest quarter and a net income (loss) attributable to parent of $-42.7 million (10-Q, period ending 2026-03-31). The company's cash and cash equivalents are dwindling, down to $130.9 million, and their short-term investments are at $221.2 million, but it's not enough to cover their liabilities of $431 million (10-Q, period ending 2026-03-31).

Syndax is a clinical-stage biopharmaceutical company focused on the development of entinostat and axatilimab, both of which are in various stages of clinical trials. The company's pipeline is their lifeline, but with research and development expenses of $58.8 million in the latest quarter, it's a lifeline that's getting more expensive by the day (10-Q, period ending 2026-03-31).

The company's inventory is growing, up $2.1 million in the latest quarter, but it's not clear if this is a sign of future sales or just a build-up of unsold stock (10-Q, period ending 2026-03-31). The company's earnings per share, diluted, are a dismal $-0.48, and their weighted average number of shares outstanding, diluted, is 88.3 million shares (10-Q, period ending 2026-03-31).

Syndax's stock price has been on a rollercoaster ride, with the company issuing multiple 144 filings in June and July, but it's not clear if this is a sign of increased interest or just a way to raise more capital (source: SEC EDGAR, https://www.sec.gov/edgar/browse/?CIK=1395937). The company's indenture with U.S. Bank Trust Company, National Association, is another sign of their financial struggles, with the trading price per $1,000 principal amount of notes less than 98% of the product of the last reported sale price of the common stock and the conversion rate (source: https://www.sec.gov/Archives/edgar/data/1395937/000119312526266027/d105044dex41.htm).

With their cash burning faster than a stack of $100 bills, Syndax Pharmaceuticals is in a race against time. They need a hit in their pipeline, and they need it fast. But with their liabilities towering over their stockholders' equity, it's a race they might not win (source: SEC EDGAR, https://www.sec.gov/Archives/edgar/data/1395937/000119312526269694/xslF345X06/ownership.xml).